Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.61 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.61 |
| ▸ | ITGAL | P20701 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565390 | 0.89 | PDE7A (0.69) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL7187676 | 0.85 | ITGB2 (0.80) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL8087222 | 0.83 | PDE7A (0.61) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL3249437 | 0.81 | PDE7A (0.59) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL3020630 | 0.81 | PDE7A (0.59) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL30388287 | 0.80 | CYP3A4 (0.56) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL15072465 | 0.80 | CYP3A4 (0.56) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL29700437 | 0.78 | PDE7A (0.55) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL7187848 | 0.78 | PDE7A (1.00) | PDE7AITGB2ICAM1ITGALCYP3A4 | |
| SCHEMBL7610324 | 0.78 | ITGB2 (0.96) | PDE7AITGB2ICAM1ITGALCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| CN-103623867-A | Composite catalyst for selective chlorination of aromatic compounds and application thereof | UNIV SOUTHEAST | 2014-03-12 | — | — | CN | disclosed |
| CN-101240119-B | Carbon black reacted with diazonium salts and products | CABOT CORP | 2011-05-11 | — | — | CN | disclosed |
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1225205-B1 | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | disclosed |
| EP-1942156-B1 | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2010-04-14 | — | — | EP | disclosed |
| CN-101240119-A | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-1175270-A | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 1998-03-04 | — | — | CN | disclosed |
| EP-0799281-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018688-A1 | CARBON BLACK REACTED WITH DIAZONIUM SALTS AND PRODUCTS | CABOT CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5157039-A | Lipoxygenase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-10-20 | — | — | US | disclosed |
| US-5109009-A | QUINOLINE AND PYRIDINE COMPOUNDS AND INHIBITION OF 5-LIPOXYGENASES THEREWITH | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-04-28 | — | — | US | disclosed |
| US-4826987-A | Pyridyl and quinoline derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1989-05-02 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3940371-A | HYDROLYTIC AND CHEMICAL STABILITY | CASE LESLIE C | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | PDE7A 1092/4885ITGB2 3675/4885ICAM1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.